HHS to study contract pharmacies for evidence of drug diversion.
HHS TO STUDY CONTRACT PHARMACY DRUG DIVERSION in response to manufacturer concerns regarding the "potential for drug diversion," the agency announced in an Aug. 23 final notice of its guidelines on contract pharmacy services for public purchasers receiving federal drug discounts under Sec. 340B of the Public Health Services Act. However, HHS said it "has received no evidence of diversion that has required an official departmental investigation."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth